A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05889988 |
Recruitment Status :
Recruiting
First Posted : June 5, 2023
Last Update Posted : January 8, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Breast Neoplasm |
Study Type : | Observational |
Estimated Enrollment : | 50 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients |
Actual Study Start Date : | June 12, 2023 |
Estimated Primary Completion Date : | June 2025 |
Estimated Study Completion Date : | June 2025 |
Group/Cohort |
---|
HER2 Metastatic Group
HER2 Metastatic Setting (defined by breast cancer that has spread outside of the breast and the immediately draining lymph node regions; stage IV)
|
HER2 Adjuvant Group
HER2 Adjuvant Setting (defined by breast cancer that is not known to have spread outside of the breast and the immediately draining lymph node regions; stages I-III). The Adjuvant Setting includes patients receiving neoadjuvant therapy.
|
- Change in chronic neuropathy symptoms [ Time Frame: Baseline, approximately 22 months ]Measured using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-induced peripheral neuropathy (CIPN) twenty-item scale (EORTC QLQCIPN20), a validated instrument designed to elicit cancer patients' experience of symptoms and functional limitations related to chemotherapy-induced peripheral neuropathy. The total score of CIPN20, each of the three subscale scores (sensory, motor, autonomic), and each individual item of the CIPN20 tool will be computed following standard scoring algorithm and converted into a 0-100 scale; higher scores indicate greater severity of neuropathy symptoms.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Planning to receive three or more doses T-DM1 for HER2-positive metastatic breast cancer (any line) or for earlier-stage breast cancer. The patient may have received one dose of T-DM1, prior to study entry if it has not been longer than 14 days since that dose and that the patient will be able to complete the required baseline questionnaire within 14 days of their first dose of T-DM1.
- Patients with previous use of neurotoxic antineoplastic agents (excluding previous use of T-DM1), pre-existing CIPN, or peripheral neuropathy secondary to other causes will be able to be enrolled in the study.
- The patient plans to continue clinical follow-up at the same institution, where the patient entered the study.
- Provide informed consent.
- Ability to complete questionnaire(s) in English by themselves or with assistance.
Exclusion Criteria:
- Previous use of T-DM1
- Concomitant use of other neurotoxic anticancer agents including cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, vincristine, eribulin, vinorelbine, thalidomide, lenalidomide, bortezomib, or epothilones. If the patient used any of these previously, then they must have been stopped for at least 7 days prior to study entry.
- Current use of commonly used drugs for the treatment of peripheral neuropathy, including duloxetine, gabapentinoids (pregabalin and gabapentin), venlafaxine, nortriptyline, or amitriptyline (including use of these medications for things other than neuropathy). If the patient used any of these previously, then they must have been stopped for at least 7 days prior to study entry.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05889988
Contact: Clinical Trials Referral Office | 855-776-0015 | mayocliniccancerstudies@mayo.edu | |
Contact: Angela M. Gosch | 507-538-0415 | Gosch.Angela@mayo.edu |
United States, Minnesota | |
Fairview Grand Itasca Clinic & Hospital | Recruiting |
Grand Rapids, Minnesota, United States, 55744 | |
Contact: Anastas Provatas, M.D. 612-624-2620 ccinfo@umn.edu | |
Principal Investigator: Anastas Provatas, M.D. | |
Fairview Range Medical Center | Recruiting |
Hibbing, Minnesota, United States, 55746 | |
Contact: Anastas Provatas, M.D. 612-624-2620 ccinfo@umn.edu | |
Principal Investigator: Anastas Provatas, M.D. | |
MMCORC CentraCare Monticello Cancer Center | Recruiting |
Monticello, Minnesota, United States, 55362 | |
Contact: Yan Ji, M.D. 612-624-2620 ccinfo@umn.edu | |
Principal Investigator: Yan Ji, M.D. | |
Fairview Northland Medical Center | Recruiting |
Princeton, Minnesota, United States, 55731 | |
Contact: Anastas Provatas, M.D. 612-624-2620 ccinfo@umn.edu | |
Principal Investigator: Anastas Provatas, M.D. | |
Mayo Clinic in Rochester | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Clinical Trials Referral Office 855-776-0015 mayocliniccancerstudies@mayo.edu | |
Principal Investigator: Charles L. Loprinzi, M.D. | |
Sanford Health Thief River Falls Clinic | Recruiting |
Thief River Falls, Minnesota, United States, 56701 | |
Contact: Amit Panwalkar, M.D. 612-624-2620 ccinfo@umn.edu | |
Principal Investigator: Amit Panwalkar, M.D. | |
Sanford Health Worthington | Recruiting |
Worthington, Minnesota, United States, 56187 | |
Contact: Jonathan Bleeker, M.D. 612-624-2620 ccinfo@umn.edu | |
Principal Investigator: Jonathan Bleeker, M.D. |
Principal Investigator: | Charles L. Loprinzi, M.D. | Mayo Clinic in Rochester |
Responsible Party: | Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT05889988 |
Other Study ID Numbers: |
MC220904 |
First Posted: | June 5, 2023 Key Record Dates |
Last Update Posted: | January 8, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ado-trastuzumab emtansine (T-DM1) Peripheral Neuropathy HER2-positive |
Breast Neoplasms Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases |
Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |